Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
暂无分享,去创建一个
J. Crowley | I. Thompson | D. Pauler | P. Goodman | C. Tangen | M. Lucia | H. Parnes | L. Minasian | L. Ford | S. Lippman | E. Crawford | C. Coltman | I. Thompson
[1] G. Murphy,et al. Purification of a human prostate specific antigen. , 1979, Investigative urology.
[2] T. Ruebush,et al. A double-blind study of trimethoprim-sulfamethoxazole prophylaxis in patients having transrectal needle biopsy of the prostate. , 1979, The Journal of urology.
[3] G. Murphy,et al. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. , 1980, Cancer research.
[4] G. Murphy,et al. Serum prostatic antigen measurement in localized prostatic cancer: correlation with clinical course. , 1982, The Journal of urology.
[5] G. Murphy,et al. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens. , 1982, Journal of the National Cancer Institute.
[6] R. Liedtke,et al. Measurement of prostate-specific antigen by radioimmunoassay. , 1984, Clinical chemistry.
[7] I. Thompson,et al. Adenocarcinoma of the prostate: results of routine urological screening. , 1984, The Journal of urology.
[8] F. Lee,et al. Transrectal ultrasound in the diagnosis of prostate cancer: Location, echogenicity, histopathology, and staging , 1986, The Prostate.
[9] L. Shaw,et al. Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers. , 1986, Urology.
[10] P. Smith,et al. Tumour markers in prostatic carcinoma. A comparison of prostate-specific antigen with acid phosphatase. , 1987, British journal of urology.
[11] H. Ragde,et al. Ultrasound-guided prostate biopsy. Biopty gun superior to aspiration. , 1988, Urology.
[12] W. Cooner,et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. , 1990, The Journal of urology.
[13] W. Catalona,et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.
[14] J. Richie,et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. , 1994, The Journal of urology.
[15] J. Oesterling,et al. Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. , 1996, Urology.
[16] R. Lamerz,et al. Screening for prostatic carcinoma with prostate specific antigen. , 1997, Anticancer research.
[17] A S Whittemore,et al. Prostate cancer incidence and mortality in the United States and the United Kingdom. , 1998, Journal of the National Cancer Institute.
[18] J. Hanley,et al. Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer , 1998 .
[19] J. Melamed,et al. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. , 1998, The Journal of urology.
[20] O. Brawley,et al. The epidemiology of prostate cancer part I: descriptive epidemiology. , 1998, Seminars in urologic oncology.
[21] F. Labrie,et al. Screening decreases prostate cancer death: First analysis of the 1988 Quebec Prospective Randomized Controlled Trial , 1999, The Prostate.
[22] J. Gohagan,et al. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. , 2000, Controlled clinical trials.
[23] D. Gunnell,et al. Comparison of trends in prostate-cancer mortality in England and Wales and the USA , 2000, The Lancet.
[24] M S Pepe,et al. Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.
[25] J. Crowley,et al. Biomarker-based methods for determining noncompliance in a prevention trial. , 2002, Controlled clinical trials.
[26] P. Humphrey,et al. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. , 2002, Urology.
[27] Michael M Lieber,et al. Journal Review , 2003, International Society of Hair Restoration Surgery.
[28] William J Catalona,et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. , 2003, The New England journal of medicine.
[29] I. Thompson,et al. The Prostate Cancer Prevention Trial: design, status, and promise , 2003, World Journal of Urology.